PL2861229T3 - Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową - Google Patents

Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Info

Publication number
PL2861229T3
PL2861229T3 PL13728758T PL13728758T PL2861229T3 PL 2861229 T3 PL2861229 T3 PL 2861229T3 PL 13728758 T PL13728758 T PL 13728758T PL 13728758 T PL13728758 T PL 13728758T PL 2861229 T3 PL2861229 T3 PL 2861229T3
Authority
PL
Poland
Prior art keywords
microbiote
tryptophane
nicotinamide
intestinal
pharmaceutical composition
Prior art date
Application number
PL13728758T
Other languages
English (en)
Inventor
Georg Waetzig
Dirk Seegert
Original Assignee
Conaris Research Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Research Institute Ag filed Critical Conaris Research Institute Ag
Publication of PL2861229T3 publication Critical patent/PL2861229T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL13728758T 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową PL2861229T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
EP13728758.7A EP2861229B1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (1)

Publication Number Publication Date
PL2861229T3 true PL2861229T3 (pl) 2021-08-09

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13728758T PL2861229T3 (pl) 2012-06-15 2013-06-14 Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową

Country Status (32)

Country Link
US (2) US10426765B2 (pl)
EP (2) EP2861229B1 (pl)
JP (3) JP6855165B2 (pl)
KR (2) KR102211832B1 (pl)
CN (2) CN108273064A (pl)
AR (1) AR091465A1 (pl)
AU (1) AU2013276451B2 (pl)
BR (1) BR112014030835B1 (pl)
CA (1) CA2876540C (pl)
CY (1) CY1123999T1 (pl)
DK (1) DK2861229T3 (pl)
ES (1) ES2859758T3 (pl)
HR (1) HRP20210090T1 (pl)
HU (1) HUE053359T2 (pl)
IL (1) IL236205B (pl)
IN (1) IN2014DN10260A (pl)
JO (1) JO3578B1 (pl)
LT (1) LT2861229T (pl)
MX (1) MX370795B (pl)
NZ (1) NZ702297A (pl)
PH (1) PH12014502744A1 (pl)
PL (1) PL2861229T3 (pl)
PT (1) PT2861229T (pl)
RS (1) RS61288B1 (pl)
RU (1) RU2657797C2 (pl)
SA (1) SA113340643B1 (pl)
SG (1) SG11201408251SA (pl)
SI (1) SI2861229T1 (pl)
SM (1) SMT202100248T1 (pl)
TW (1) TWI624260B (pl)
WO (1) WO2013186355A1 (pl)
ZA (1) ZA201408922B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ702297A (en) 2012-06-15 2016-11-25 Conaris Res Inst Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
DK3003298T3 (da) * 2013-06-05 2024-06-17 Univ British Columbia Antifibrogene forbindelser, fremgangsmåder og anvendelser deraf
WO2014200347A1 (en) * 2013-06-14 2014-12-18 Ferring B.V. Extended release nicotinamide formulation
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
WO2015086843A2 (en) * 2013-12-13 2015-06-18 Conaris Research Institute Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
HK1223840A1 (zh) 2013-12-13 2017-08-11 Conaris Research Institute Ag 用於有益地影响肠道微生物丛和/或治疗胃肠道炎症的含有烟醯胺和5-氨基水杨酸的组合的药物组合物
WO2015124637A1 (en) * 2014-02-18 2015-08-27 Conaris Research Institute Ag Methods and compositions for intestinal microenvironment transfer
BR112016024400A2 (pt) * 2014-05-12 2017-08-15 Unilever Nv uso de niacinamida, niacinamida e método para melhorar a proteção do couro cabeludo
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula
BR112018071363A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
US10874617B2 (en) 2016-04-19 2020-12-29 Ferring B.V. Oral pharmaceutical compositions of mesalazine
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
JPWO2020166527A1 (ja) * 2019-02-12 2021-12-16 めぐみ 田中 乳幼児用飲食品、乳幼児の腸内環境の改善方法、及び乳幼児の免疫力の増強方法
JP7493207B2 (ja) * 2019-03-28 2024-05-31 国立大学法人東北大学 がんの予防又は治療剤
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
EP4251157A1 (en) * 2020-11-27 2023-10-04 CONARIS research institute AG Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
CN116635025A (zh) * 2020-11-27 2023-08-22 康纳里斯研究院股份公司 用于缩短covid-19和其他病毒感染患者的症状消退时间的烟酰胺、烟酰胺前体和烟酰胺代谢物及其组合物
WO2023002939A1 (ja) * 2021-07-19 2023-01-26 明治ホールディングス株式会社 炎症性腸疾患の予防又は改善のための組成物、及び腸内細菌叢調節のための組成物
WO2023187003A1 (en) * 2022-03-30 2023-10-05 Conaris Research Institute Ag Composition comprising nicotinamide, nicotinamide precursors, nicotinamide metabolites or combinations thereof for preventing or reducing one or more post-acute symptoms of infectious diseases
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커
CN117837697A (zh) * 2023-12-22 2024-04-09 汕头大学 一种烟酰胺的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) * 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
JP2002533415A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤およびニコチン酸誘導体の組み合わせ
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
WO2002011725A1 (en) 2000-08-08 2002-02-14 Shionogi & Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US7417037B2 (en) 2004-01-20 2008-08-26 The Board Of Regents Of The University Of Oklahoma Compositions and methods of treatment for inflammatory diseases
US7326809B2 (en) 2004-05-27 2008-02-05 Antibe Therapeutics Inc. Salts of 4- or 5-aminosalicylic acid
EP1814530A2 (en) * 2004-09-27 2007-08-08 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule-formulations
EP1920770A4 (en) 2005-07-01 2010-09-29 Ajinomoto Kk THERAPEUTIC AGENT AGAINST INFLAMMATORY DISEASE AND TNF ALPHA PRODUCTION DISEASE
CA2657606A1 (en) * 2006-03-08 2007-09-13 Cortria Corporation Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
EP2214518A4 (en) * 2007-10-19 2011-06-29 Joel D Pardee METABOLIC IMPROVEMENT TREATMENT
US20110104282A1 (en) * 2008-04-25 2011-05-05 Karolinska Institutet Innovations Ab New Therapy of Treatment of the Irritable Bowel Syndrome
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
US20110123575A1 (en) * 2008-06-02 2011-05-26 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
EA022886B1 (ru) 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
NZ702297A (en) 2012-06-15 2016-11-25 Conaris Res Inst Ag A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
WO2014200347A1 (en) 2013-06-14 2014-12-18 Ferring B.V. Extended release nicotinamide formulation
BR112018071363A2 (pt) 2016-04-19 2019-02-05 Ferring Bv composições farmacêuticas orais de nicotinamida
EP4251157A1 (en) * 2020-11-27 2023-10-04 CONARIS research institute AG Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections

Also Published As

Publication number Publication date
JP2022017332A (ja) 2022-01-25
HK1204972A1 (en) 2015-12-11
WO2013186355A1 (en) 2013-12-19
JP2019069972A (ja) 2019-05-09
JP2015519388A (ja) 2015-07-09
CA2876540C (en) 2022-11-29
IL236205B (en) 2020-02-27
ES2859758T3 (es) 2021-10-04
ZA201408922B (en) 2016-10-26
AU2013276451B2 (en) 2018-03-29
SG11201408251SA (en) 2015-01-29
AR091465A1 (es) 2015-02-04
SI2861229T1 (sl) 2021-03-31
LT2861229T (lt) 2021-01-25
PT2861229T (pt) 2021-01-05
BR112014030835A2 (pt) 2017-06-27
RS61288B1 (sr) 2021-02-26
PH12014502744A1 (en) 2015-02-02
SMT202100248T1 (it) 2021-05-07
EP3831379A1 (en) 2021-06-09
MX2014015217A (es) 2015-03-05
KR102211832B1 (ko) 2021-02-02
NZ702297A (en) 2016-11-25
BR112014030835B1 (pt) 2022-01-11
DK2861229T3 (da) 2021-01-18
US20200009124A1 (en) 2020-01-09
CN104363907A (zh) 2015-02-18
MX370795B (es) 2020-01-08
US10426765B2 (en) 2019-10-01
EP2861229A1 (en) 2015-04-22
RU2657797C2 (ru) 2018-06-15
EP2861229B1 (en) 2020-12-23
CY1123999T1 (el) 2022-05-27
TWI624260B (zh) 2018-05-21
IN2014DN10260A (pl) 2015-08-07
SA113340643B1 (ar) 2019-10-06
CN108273064A (zh) 2018-07-13
HUE053359T2 (hu) 2021-06-28
JO3578B1 (ar) 2020-07-05
KR20150021071A (ko) 2015-02-27
US20150126462A1 (en) 2015-05-07
KR20200011619A (ko) 2020-02-03
TW201400116A (zh) 2014-01-01
HRP20210090T1 (hr) 2021-03-05
CA2876540A1 (en) 2013-12-19
IL236205A0 (en) 2015-01-29
EP3831379B1 (en) 2025-09-10
AU2013276451A1 (en) 2015-01-15
JP6855165B2 (ja) 2021-04-07
RU2014148239A (ru) 2016-08-10

Similar Documents

Publication Publication Date Title
PL2861229T3 (pl) Kompozycja farmaceutyczna zawierająca kwas nikotynowy i/lub nikotynamid i/lub tryptofan do pozytywnego wpływu na mikrobiotę jelitową
CO6970616A2 (es) Composición herbicida que contiene ácido de 4-amino-3-cloro-6-(4-cloro-2-flúor -3-metoxifenil) piridina-2-carboxílico, o los derivados del mismo y fluroxipir, o los derivados del mismo
DK2742019T3 (da) N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse
CO6910189A2 (es) Derivado heterociclico y farmacéutico
CO7071126A2 (es) Derivados de piridona
IL236852A0 (en) Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and certain ps ii inhibitors
HUE054178T2 (hu) Metil/fluor-piridinil-metoxi-szubsztituált piridinon-piridinil-vegyületek és fluor-pirimidinil-metoxi-szubsztituált piridinon-piridinil-vegyületek
LT2892912T (lt) Oleanolio rūgšties c17-alkandiilo ir alkendiilo dariniai bei jų panaudojimo būdai
IL236863A0 (en) Herbicidal compositions comprising 4-amino-3-chloro-5-fluoro-6-(4-chloro-2-fluoro-3-methoxyphenyl)pyridine-2-carboxylic acid or a derivative thereof and imidazolinones
HUE063581T2 (hu) Aeroszol pirfenidon és piridon analóg vegyületek
HUE037736T2 (hu) Piridin származékok
IL236499A0 (en) Compounds that suppress nicotinamide phosphoribosyltransferase (nampt), preparations containing them and their uses
BR112014027561A2 (pt) moduladores alostéricos dos receptor acetilcolina alfa 7 nicotínicos, seus derivados e respectivas utilizações
PT2706062T (pt) Novos derivados da cefalosporina e sua composição farmacêutica
DK2917181T3 (da) Heteroarylderivater og anvendelser deraf
PT3079675T (pt) Uma composição farmacêutica que contém ácido nicotínico e/ou nicotinamida para utilização para influenciar beneficamente os níveis de lípidos no sangue através da modificação da microbiota intestinal
IL238370A0 (en) n-(pyridin-2-yl)pyrimidine-4-amine derivatives containing a sulfoximine group
IL256646B (en) History of azaquinazoline carboxamides and pharmaceutical preparations containing them
EP2810941A4 (en) NOVEL PIPERIN DERIVATIVE AND USE THEREOF
ZA201305227B (en) Pharmaceutical composition comprising pyridone derivatives
IL238059A0 (en) History of pyrrolidine, and pharmaceutical preparations containing them
EP2789607A4 (en) PYRIDONE DERIVATIVE AND MEDICAMENT THEREFOR
SG11201406942SA (en) Trans-2-decenoic acid derivative and drug containing same
CL2015001778A1 (es) Composiciones herbicidas que contienen ácido de 4-amino-3-cloro-6-(4-cloro-2-flúor-3-metoxifenil) piridina-2-carboxílico o un derivado del mismo y flufenacet
IL240447A (en) Propionic Acid-Baryl Acid Derivatives and Their Use as Pharmaceutical Preparations